 Upon reviewing Protagenic Therapeutics Incs NASDAQ: PTIX Investigational New Drug IND application for its lead compound, PT00114, the FDA has currently rejected the Companys IND. The application sought approval to start a Phase 12a basket study designed to test PT00114 in healthy volunteers and patients with PTSD, anxiety, and depression. 